Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:2509-2515
Published online before print May 22, 2006, doi: 10.1161/CIRCULATIONAHA.105.601930
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
113/21/2509    most recent
CIRCULATIONAHA.105.601930v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elliott, C. G.
Right arrow Articles by Ward, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elliott, C. G.
Right arrow Articles by Ward, K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Genetics Home Reference
Medline Plus Health Information
*Pulmonary Hypertension
Related Collections
Right arrow Pulmonary biology and circulation
Right arrow Genetics of cardiovascular disease

(Circulation. 2006;113:2509-2515.)
© 2006 American Heart Association, Inc.


Genetics

Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension

C. Gregory Elliott, MD; Eric W. Glissmeyer, BS; Gregory T. Havlena, BS; John Carlquist, PhD; Jason T. McKinney, MS; Stuart Rich, MD; Michael D. McGoon, MD; Mary Beth Scholand, MD; Miryoung Kim, BS; Robert L. Jensen, PhD; Jon W. Schmidt; Kenneth Ward, MD

From the LDS Hospital and the University of Utah School of Medicine (C.G.E., E.W.G., G.T.H., J.C., M.B.S., M.K., R.L.J., J.W.S.), Salt Lake City, Utah; Johns Hopkins University School of Medicine (G.T.H.), Baltimore, Md; the University of Hawaii (K.W.), Honolulu; the Mayo Clinic College of Medicine (M.D.M.), Rochester, Minn; the University of Chicago (S.R.), Chicago, Ill; and Idaho Technology, Inc (J.T.M.), Salt Lake City, Utah.

Correspondence to C. Gregory Elliott, MD, Pulmonary Division, LDS Hospital, 8th Ave and C St, Salt Lake City, UT 84143. E-mail ldgellio{at}ihc.com

Received November 17, 2005; revision received February 6, 2006; accepted March 24, 2006.

Background— Vasoreactivity tests are fundamental in evaluating pulmonary arterial hypertension (PAH). Mutations of the transforming growth factor-ß type II receptor gene, BMPR2, predispose to the development of pulmonary hypertension and may alter the response to vasodilators. Previous investigations have not examined the relationship of BMPR2 mutations to vasoreactivity.

Methods and Results— We identified 133 consecutive unrelated patients with either idiopathic or familial PAH. Sixty-six patients were excluded because we lacked either DNA samples (n=18) or complete data from a vasoreactivity test (n=48). The remaining 67 patients were screened for BMPR2 DNA sequence variations, and specific variations were confirmed by gene sequencing. The vasoreactivity of patients with nonsynonymous BMPR2 variations was compared with that of patients without nonsynonymous BMPR2 variations. We found nonsynonymous BMPR2 variations in 27 of 67 patients with idiopathic (n=16 of 52) or familial (n=11 of 15) PAH. Vasoreactivity was identified in 3.7% of 27 patients with nonsynonymous BMPR2 variations and in 35% of 40 patients without nonsynonymous BMPR2 variations (P=0.003). Five of the 27 nonsynonymous variations occur commonly in healthy individuals. None of the remaining 22 patients with BMPR2 variations demonstrated vasoreactivity, and the analysis remained unchanged when we assumed that nonsynonymous BMPR2 variations were present in all 15 patients with familial PAH.

Conclusions— Patients with familial or idiopathic PAH and nonsynonymous BMPR2 variations are unlikely to demonstrate vasoreactivity. Further trials are required to determine whether long-term therapy can be directed by tests for BMPR2 variations.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
L. J. Rubin
BMPR2 Mutation and Outcome in Pulmonary Arterial Hypertension: Clinical Relevance to Physicians and Patients
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1300 - 1301.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
B. Sztrymf, F. Coulet, B. Girerd, A. Yaici, X. Jais, O. Sitbon, D. Montani, R. Souza, G. Simonneau, F. Soubrier, et al.
Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1377 - 1383.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Lagna, M. M. Ku, P. H. Nguyen, N. A. Neuman, B. N. Davis, and A. Hata
Control of Phenotypic Plasticity of Smooth Muscle Cells by Bone Morphogenetic Protein Signaling through the Myocardin-related Transcription Factors
J. Biol. Chem., December 21, 2007; 282(51): 37244 - 37255.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Jain, H. Ventura, and B. deBoisblanc
Pathophysiology of Pulmonary Arterial Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 104 - 109.
[Abstract] [PDF]